BNP Paribas Financial Markets Purchases 398,648 Shares of Amarin Co. plc (NASDAQ:AMRN)

BNP Paribas Financial Markets lifted its position in Amarin Co. plc (NASDAQ:AMRNFree Report) by 705.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 455,177 shares of the biopharmaceutical company’s stock after acquiring an additional 398,648 shares during the period. BNP Paribas Financial Markets owned 0.11% of Amarin worth $396,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its position in shares of Amarin by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 34,725 shares in the last quarter. SVB Wealth LLC increased its position in Amarin by 100.0% during the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 30,000 shares in the last quarter. Gilliland Jeter Wealth Management LLC bought a new position in Amarin during the 4th quarter valued at approximately $64,000. Waterfront Wealth Inc. increased its position in Amarin by 18.0% during the 4th quarter. Waterfront Wealth Inc. now owns 386,735 shares of the biopharmaceutical company’s stock valued at $336,000 after buying an additional 58,942 shares in the last quarter. Finally, LCM Capital Management Inc increased its position in Amarin by 5.1% during the 4th quarter. LCM Capital Management Inc now owns 740,159 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 36,000 shares in the last quarter. Institutional investors own 22.25% of the company’s stock.

Amarin Stock Down 1.4 %

AMRN stock opened at $0.85 on Tuesday. Amarin Co. plc has a twelve month low of $0.65 and a twelve month high of $1.49. The firm has a market cap of $350.18 million, a PE ratio of -7.11 and a beta of 1.99. The business has a 50 day moving average of $0.91 and a 200 day moving average of $0.96.

Amarin (NASDAQ:AMRNGet Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.02. Amarin had a negative return on equity of 9.48% and a negative net margin of 18.96%. The company had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. During the same quarter last year, the company earned ($0.04) EPS. On average, research analysts expect that Amarin Co. plc will post -0.18 earnings per share for the current fiscal year.

Amarin Company Profile

(Free Report)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

See Also

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.